Milliman estimates that plans’ aggregate funding improved by $26 billion in the first half of 2025, moving from a $23 billion shortfall at year-end 2024 to a $3 billion surplus as of June 30, 2025.

Unfortunately, this book can't be printed from the OpenBook. If you need to print pages from this book, we recommend downloading it as a PDF. Visit NAP.edu/10766 to get more information about this ...

As the most widely used viral vector for gene therapies, Adeno-Associated Viruses (AAVs) present unique advantages, including their ability to enter both dividing and non-dividing cells, the absence ...

The Draft Guidance provides an extensive overview of sponsors’ safety reporting requirements. However, in addition to general IND safety reporting requirements, a major focus is updated ...

The process of translating a biotherapeutic from the laboratory to the market is highly regulated and inherently complex. Approval requires comprehensive analytical characterization, including ...

Enterprise AI has a data problem. Despite billions in investment and increasingly capable language models, most organizations still can't answer basic analytical questions about their document ...